Form 4 for DXCM Dexcom
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-16 · accession 0001093557-24-000190 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-17 | 2024-12-16 | DXCM | Leach Jacob Steven | EVP, COO | S - Sale | $76.87 | -744 | 264.2K | -0.3% | -$57.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-16 | S | D | 744 | $76.87 | 264,171 | D | — | — | (F1) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. (F2) Included in this number are 51,972 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 16,931 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 8,988 of which were granted on March 8, 2022 and shall vest through March 8, 2025. |